Journal of Clinical Medicine, Год журнала: 2025, Номер 14(6), С. 1856 - 1856
Опубликована: Март 10, 2025
The extracellular matrix (ECM) is the common denominator of more than 50 chronic diseases. Some these pathologies lead to enhanced tissue formation and deposition, whereas others are associated with increased degradation, some exhibit a combination both, leading severe alterations. To develop effective therapies for diseases affecting lung, liver, kidney, skin, intestine, musculoskeletal system, heart, solid tumors, we need modulate ECM’s composition restore its organization function. Across diverse organ diseases, there denominators distinguishing factors in this fibroinflammatory axis, which may be used foster new insights into drug development across disease indications. 2nd Extracellular Matrix Pharmacology Congress took place Copenhagen, Denmark, from 17 19 June 2024 was hosted by International Society Pharmacology. event attended 450 participants 35 countries, among whom were prominent scientists who brought together state-of-the-art research on asked important questions facilitate development. We highlight key aspects ECM lungs, tumors advance our understanding central targets also advances tools technology that enable development, thereby supporting ECM.
Язык: Английский